HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kobayashi, I. Articles by Fujioka, T. Search for Related Content PubMed PubMed Citation Articles by Kobayashi, I. Articles by Fujioka, T. Agricola Articles by Kobayashi, I. Articles by Fujioka, T.

Helicobacter pylori isolated from patients who later failed H. pylori eradication triple therapy readily develop resistance to clarithromycin

¹ Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., 3-30-1 Shimura, Itabashi-ku, Tokyo 174-8555, Japan

² Department of General Medicine, Faculty of Medicine, Oita University, Hasama-machi, Oita 879-5593, Japan

Correspondence
Intetsu Kobayashi
mbc-ka{at}sa2.so-net.ne.jp

Received 6 September 2005
Accepted 3 February 2006

	INTRODUCTION

TOP INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
According to the Gastroenterology Society of Japan guidelines for the eradication of Helicobacter pylori infection, the ideal eradication therapy for infected gastric or duodenal ulcer patients is a combination regimen consisting of clarithromycin plus amoxicillin plus a proton pump inhibitor. Eradication rates with this triple therapy have been reported to be as high as 80–90 % (European Helicobacter pylori Study Group, 1997), although they varied by medical institution (van den Hulst et al., 1996; Ducóns et al., 1999; Broutet et al., 2001). However, the current lack of an established second-line therapy for patients in whom eradication of clarithromycin-resistant H. pylori strains is unsuccessful is a serious issue. In addition, reports exist describing patients infected with clarithromycin-susceptible strains in whom H. pylori eradication was still unsuccessful (Ducóns et al., 1999); the mechanism for this failure remains unclear.

In the present study, we investigated the ease of induction of clarithromycin resistance in clarithromycin-susceptible strains of H. pylori isolated prior to the eradication therapy, both from patients in whom the eradication therapy was successful (the successful eradication group) and from those in whom it was ultimately unsuccessful (the unsuccessful eradication group).

	METHODS

TOP INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
Bacterial strains. Clarithromycin-susceptible H. pylori strains were isolated from infected gastric ulcer or duodenal ulcer patients, as described previously (Suzuki et al., 1999), before the patients were treated with the triple-combination eradication therapy in accordance with the guidelines for the diagnosis and therapy of H. pylori infection (Japanese Society for Helicobacter Research, 2000). Sixteen clarithromycin-susceptible strains were used in the study, comprising ten strains isolated from patients in the successful eradication group and six from patients in the unsuccessful eradication group. The effect of eradication therapy (successful or unsuccessful) was determined according to the guidelines mentioned above.

Antibiotics and determination of antimicrobial susceptibility. Clarithromycin obtained from Taisho Pharmaceutical was used to select resistant mutants and for measurement of the MIC. The MIC of clarithromycin was determined by the agar dilution method, according to the guidelines established by the NCCLS (2003). Mueller–Hinton agar (Difco Laboratories) plates containing 5 % sheep blood and serial 2-fold dilutions of clarithromycin were inoculated with 1–3 µl of a saline suspension of the H. pylori isolates equivalent to a 2.0 McFarland standard (1x10⁷–1x10⁸ c.f.u. ml^–1). Plates were incubated for 72 h at 35 °C in a microaerophilic atmosphere. The MIC was defined as the lowest concentration of clarithromycin that completely inhibited bacterial growth.

Selection of clarithromycin resistance. Clarithromycin-resistant mutants were generated by the serial-passage method. A 72 h growth of each strain on blood agar base no. 2 (Oxoid) supplemented with 5 % defibrinated horse blood was inoculated using a swab onto the blood agar containing clarithromycin at a concentration of 0.5x MIC. The surface growth after 72 h incubation was subcultured onto medium containing the same and twice the previous concentration of clarithromycin. This procedure was repeated ten times serially, using the surface growth on medium containing progressively increasing concentrations of clarithromycin.

Statistical analysis. Statistical analysis was performed by Student's t-test. A statistically significant difference was defined as having a value of P<0.02.

Detection of point mutations. Point mutations at A2142 or A2143 of the 23S rRNA gene were identified by the PCR-RFLP method described by Versalovic et al. (1997). Chromosomal DNA was isolated from approximately ten colonies of each strain by phenol/chloroform extraction and ethanol precipitation. PCR amplification of the domain V region of the 23S rRNA gene was performed with the primers 5'-AGTCGGGACCTAAGGCGAG-3' and 5'-TTCCCGCTTAGATGCTTTCAG-3'. The conditions for amplification were as follows: pre-denaturation at 94 °C for 3 min, followed by 40 cycles of denaturation at 94 °C for 1 min, annealing at 50 °C for 2 min and extension at 72 °C for 2 min, with post-extension at 72 °C for 7 min. For detection of the A2142G and A2143G mutations, 7.5 U MboII (Takara Shuzo) or 5 U BsaI (New England Biolabs) were added to each PCR product and digestions were performed for 14 h at 55 or 37 °C, respectively. The digested PCR products were analysed by electrophoresis on a 1 % agarose gel and stained with ethidium bromide.

	RESULTS

TOP INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
Clarithromycin MICs for the mutant and parent strains

The number of transfers required to select resistance in the test strains obtained from patients in the successful and unsuccessful eradication groups and the respective MICs are shown in Table 1. The clarithromycin MIC for all ten of the original strains (B1–B10) isolated from patients in the successful eradication group was 0.015 µg ml^–1. By the third transfer, the MIC for strain B4 had increased 8-fold compared with the original strain and thereafter increased a further 4-fold, but still remained comparatively low at 0.5 µg ml^–1, even at the tenth transfer. In contrast, the MICs for strains B3 and B8 increased greatly at the fifth transfer and increased further to 128 µg ml^–1 or more by the tenth transfer. In addition, the MIC for strain B9 increased at the eighth transfer and was 64 µg ml^–1 at the tenth transfer. There were few changes in the MICs for the other strains, with MIC values of 0.5 µg ml^–1 by the tenth transfer.

Mean number of transfers

The mean number of transfers required for the MIC to increase by 8-fold or more after the selection of resistance was compared between the isolates from the two groups of patients (Table 2). A much smaller number of transfers was required for the MICs to increase by 8-, 16-, 32- or 64-fold for isolates obtained from patients in the unsuccessful eradication group.

	DISCUSSION

TOP INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
The reported eradication rates following triple-combination therapy vary with the medical institution and range widely from 70 to 95 % (van den Hulst et al., 1996; Ducóns et al., 1999; Broutet et al., 2001). These differences among medical institutions may be attributable to the rate of resistance of H. pylori to clarithromycin during the early stage of eradication therapy. According to Murakami et al. (2002), the eradication rates following triple-combination therapy in patients infected with clarithromycin-resistant strains may be as low as 8 % and extremely low compared with the typical eradication rate. However, the eradication rate of strains for which elevated MICs were observed, but which were still susceptible to amoxicillin, was not as low. These findings suggest that clarithromycin may play a major role in the eradication of H. pylori.

The mechanisms of resistance to macrolides, the antibiotic category to which clarithromycin belongs, are generally accepted to be: (i) inactivation of enzyme (hydrolysis and modification: ereA, ereB and phosphotransferase), (ii) low accumulation (active efflux and low membrane permeability: erpA and msrA) and (iii) changes in the target regions (changes in rRNA: ermA mutation in the 23S rRNA gene), and vary greatly according to the bacterial species (Tait-Kamradt et al., 2000). Resistance of H. pylori to clarithromycin is usually due to mutation in the 23S rRNA gene. Moreover, it has been reported that these organisms readily become resistant to clarithromycin when they are exposed to the drug at sub-MIC levels (Haas et al., 1990). In a previous study, we detected clarithromycin resistance at a high frequency after eradication therapy with a regimen containing clarithromycin (Kobayashi et al., 1996). It would be reasonable to assume that the resistant strains were selected during exposure to clarithromycin based on the evidence that susceptible strains were isolated before the treatment (Kim et al., 2003); furthermore, spontaneous resistance is rare in H. pylori (Taylor et al., 1997). In our previous study, strains isolated before eradication therapy that were obtained from patients in the unsuccessful eradication group were resistant to clarithromycin and had the A2143G or A2142G point mutation. Since these patients had no previous history of eradication therapy for H. pylori, it is highly possible that the resistance had been selected previously in these H. pylori strains by macrolides given to the patients in the past.

In the present study, the development of resistance to the drug followed one of two patterns, i.e. the strains became resistant to clarithromycin after a small number of exposures or the strains became resistant to clarithromycin in a stepwise manner after long-term exposure to the drug. This suggests that there are strains that can readily develop resistance to clarithromycin following short-term exposure to the drug administered in vivo. The mechanism underlying such a rapid development of resistance to clarithromycin has not yet been clarified, but resistance of the strains to the drug is considered to be selected at an early stage due to the development of mutations in the originally susceptible strains. Fontana et al. (2002) have reported that the T2717C mutation of domain VI is present specifically in moderately resistant strains at a clarithromycin MIC of 1 µg ml^–1, which differs from the A2142G and A2143G mutations of domain V of the 23S rRNA gene reported to date. No T2717C mutation was detected in the strains that readily became resistant to clarithromycin in our previous investigation (data not shown). In addition, in Japan, there are very few reports of strains developing resistance at a clarithromycin MIC of 1 µg ml^–1 (Kobayashi et al., 2001) as shown by Fontana et al. (2002). Therefore, the mechanism underlying the rapid development of resistance in the strains in the present study is presumed to be different from that in the aforementioned strains.

The above results indicate that, among the clinically isolated H. pylori strains in this study, there were strains that readily became resistant, even after only a small number of transfers with exposure to clarithromycin at sub-MIC levels, and careful attention should be paid to eradication therapy with regimens containing mainly clarithromycin in patients infected with these strains. Further investigation is needed to determine the mechanism of such rapid development of resistance to clarithromycin in these strains, which would be the key to inhibiting the increase in the number of resistant organisms.

	REFERENCES

TOP INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
Broutet, N., Marais, A., Lamouliatte, H., de Mascarel, A., Samoyeau, R., Salamon, R. & Mégraud, F. (2001). cagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol 39, 1319–1322.[Abstract/Free Full Text]

Ducóns, J. A., Santolaria, S., Guirao, R., Ferrero, M., Montoro, M. & Gomollón, F. (1999). Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxicillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 13, 775–780.[CrossRef][Medline]

European Helicobacter pylori Study Group (1997). Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41, 8–13.[Abstract/Free Full Text]

Fontana, C., Favaro, M., Minelli, S., Criscuolo, A. A., Pietroiusti, A., Galante, A. & Favalli, C. (2002). New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother 46, 3765–3769.[Abstract/Free Full Text]

Haas, C. E., Nix, D. E. & Schentag, J. J. (1990). In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 34, 1637–1641.[Abstract/Free Full Text]

Japanese Society for Helicobacter Research (2000). Guidelines for diagnosis and treatment of Helicobacter pylori infection. Jpn J Helicobacter Res 2, 2–12 (in Japanese).

Kim, J. J., Kim, J. G. & Kwon, D. H. (2003). Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patients and underestimation of antimicrobial susceptibility testing. Helicobacter 8, 202–206.[CrossRef][Medline]

Kobayashi, I., Toda, H., Hasegawa, M., Nishida, M., Fujioka, T. & Nasu, M. (1996). Drug susceptibility of Helicobacter pylori freshly isolated from gastrointestinal mucosa of patients with peptic ulcer. Jpn J Chemother 14, 719–722 (in Japanese with English summary).

Kobayashi, I., Saika, T., Muraoka, H., Inoue, M. & Nasu, M. (2001). Relationship between clarithromycin breakpoint for Helicobacter pylori and point mutation in 23S rRNA gene. Jpn J Chemother 46, 236–240 (in Japanese with English summary).

Murakami, K., Sato, R., Okimoto, T., Nasu, M., Fujioka, T., Kodama, M., Kagawa, T., Sato, S., Abe, H. & Arita, T. (2002). Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 16, 1933–1938.[CrossRef][Medline]

NCCLS (2003). Performance standards for antimicrobial susceptibility testing. Thirteenth informational supplement M100-S13. Wayne, PA: NCCLS.

Suzuki, J., Muraoka, H., Kobayashi, I., Fujita, T. & Mine, T. (1999). Rare incidence of interspousal transmission of Helicobacter pylori in asymptomatic individuals in Japan. J Clin Microbiol 37, 4174–4176.[Abstract/Free Full Text]

Tait-Kamradt, A., Davies, T., Cronan, M., Jacobs, M. R., Appelbaum, P. C. & Sutcliffe, J. (2000). Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 44, 2118–2125.[Abstract/Free Full Text]

Taylor, D. E., Ge, Z., Purych, D., Lo, T. & Hiratsuka, K. (1997). Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother 41, 2621–2628.[Abstract]

van den Hulst, R. W., Keller, J. J., Rauws, E. A. & Tytgat, G. N. (1996). Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1, 6–19.[Medline]

Versalovic, J., Osato, M. S., Spakovsky, K. & 7 other authors (1997). Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 40, 283–286.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. P. Gisbert Review: Second-line rescue therapy of Helicobacter pylori infection Therapeutic Advances in Gastroenterology, November 1, 2009; 2(6): 331 - 356. [Abstract] [PDF]

				S.-H. Xuan, Y.-G. Zhou, B. Shao, Y.-L. Cui, J. Li, H.-B. Yin, X.-P. Song, H. Cong, F.-X. Jing, Q.-H. Jin, et al. Enzymic colorimetry-based DNA chip: a rapid and accurate assay for detecting mutations for clarithromycin resistance in the 23S rRNA gene of Helicobacter pylori J. Med. Microbiol., November 1, 2009; 58(11): 1443 - 1448. [Abstract] [Full Text] [PDF]

				K.-A. Moder, F. Layer, W. Konig, and B. Konig Rapid screening of clarithromycin resistance in Helicobacter pylori by pyrosequencing J. Med. Microbiol., October 1, 2007; 56(10): 1370 - 1376. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kobayashi, I. Articles by Fujioka, T. Search for Related Content PubMed PubMed Citation Articles by Kobayashi, I. Articles by Fujioka, T. Agricola Articles by Kobayashi, I. Articles by Fujioka, T.